SFI
LFCR icon

Susquehanna Fundamental Investments’s Lifecore Biomedical LFCR Stock Holding History

Susquehanna Fundamental Investments’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-13,227
Closed -$140K – 1717
2021
Q1 		$140K Sell
13,227
-3,832
-22% -$43.1K ﹤0.01% 1435
2020
Q4 		$185K Buy
+17,059
New +$176K ﹤0.01% 1362

Other funds holding LFCR

WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CSC
Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ICOM
Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Susquehanna Fundamental Investments's LFCR Position: Q2 2021 in Review

Susquehanna Fundamental Investments sold out of Lifecore Biomedical (LFCR) in Q2 2021, closing a stake of 13,227 shares — an estimated $140K sold.

Susquehanna Fundamental Investments first reported a position in LFCR in Q4 2020 and held it in 2 quarters. The position peaked at $185K in Q4 2020. 95 funds tracked by Wall St. Rank hold LFCR as of Q2 2021.

  • Susquehanna Fundamental Investments reported no remaining Lifecore Biomedical position as of Q2 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 13,227 Lifecore Biomedical shares in Q2 2021, an estimated $140K.
  • Susquehanna Fundamental Investments first reported a position in Lifecore Biomedical in Q4 2020 and held it in 2 quarters.
  • Susquehanna Fundamental Investments's Lifecore Biomedical position peaked at $185K in Q4 2020.
  • 95 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2021, filed 11 Aug 2021.